Open Site Navigation

More than 60 Years of Use Outside the US

OMZYA® in Clinical Development for Commercialization in the US

Sodium & Calcium Channel Blocking Mechanism

Potential Dual Mechanism for Relief of Muscle Spasm

  • New Chemical Entity (NCE)

  • Composition of matter IP coverage to 2032 with possible patent term extension to 2037

  • Exclusive worldwide development and commercialization rights


  • Approved outside of the US since 1959 (24 countries)

  • Primary indication: therapeutic treatment of post-stroke spasticity

  • Widely used in parts of Europe, South America and Asia



Overcame Hurdle to Seek Approval in the US

(4-MMPPO as a degradant in the tolperisone used ex-US)

American Society of Interventional Pain Physicians Meeting (ASIPP)

Neurana's CMO, Dr. Randall Kaye, MD, presents at the 23rd Annual ASIPP Meeting. The abstract, one of only twelve selected for presentation details, “The Effects of Tolperisone on Simulated Driving Performance, Drowsiness, and Cognitive Function: Comparison with Cyclobenzaprine and Placebo in a Phase 1, Randomized, 4-Period, Crossover Study”.